Samjin Pharmaceuticals (005500) Fundamentals 2026 — P/E 9.9x, Revenue Analysis | SniperIQ
Samjin Pharmaceuticals (005500) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩222.5B, trading at ₩17580.00 on the KSC. This SniperIQ fundamentals page covers Samjin Pharmaceuticals's valuation (P/E 9.9x, P/B 0.8x), profitability (net margin 7.1%), revenue (₩309.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Samjin Pharmaceuticals's market cap?
Samjin Pharmaceuticals (005500) has a market capitalization of approximately ₩222.5B, trading at ₩17580.00 on the KSC. Market cap moves with the live share price.
What is Samjin Pharmaceuticals's P/E ratio?
Samjin Pharmaceuticals's trailing twelve-month P/E ratio is 9.9x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Samjin Pharmaceuticals?
Samjin Pharmaceuticals runs a net profit margin of 7.1%, a gross margin of 46.4%, and an operating margin of 7.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Samjin Pharmaceuticals generate?
Samjin Pharmaceuticals reported revenue of ₩309.1B for fiscal year 2025, with net income of ₩24.2B and earnings per share (EPS) of 1962.68. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Samjin Pharmaceuticals pay a dividend?
Samjin Pharmaceuticals offers a trailing dividend yield of about 4.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Samjin Pharmaceuticals financially healthy?
Samjin Pharmaceuticals carries a debt-to-equity ratio of 0.43x and a current ratio of 1.28x, with a market beta of 0.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Samjin Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Samjin Pharmaceuticals (005500) the key facts are: market cap ₩222.5B, P/E 9.9x, revenue ₩309.1B, 52-week range 16990-25900. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Samjin Pharmaceuticals's full fundamentals live
Get Samjin Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.